European Medicines Agency Grants NeuroSense SME Status

  • SME status offers regulatory guidance and engagement in dialogue with EMA
  • NeuroSense to open an EU office in Ulm, Germany
  • Company plans to enroll patients at multiple sites across Europe in its planned Phase 3 pivotal ALS study of PrimeC


Join Our Newsletter

Skip to content